Table 2.
Histopathological analysis of demyelination damage in spinal cord (S) and brain cortex (B) of C16 dose dependent treated group.
| 2 weeks | Control 2 w | C16 0.5 mg 2 w (Low dose group) |
C16 1 mg 2 w | C16 2 mg 2 w |
|---|---|---|---|---|
| Spinal cord | 3.60 ± 0.57 | 1.40 ± 0.56* (P = 0.0023 versus control*) |
1.39 ± 0.50∗#
(P = 0.001 versus control*; P = 0.039 versus low dose group#) |
0.80 ± 0.45∗$
(P = 0.00013 versus control*; P = 0.006 versus low dose$) |
| Brain cortex | 3.20 ± 0.44 | 1.60 ± 0.55* (P = 0.001 versus control*) |
1.20 ± 0.45∗#
(P = 0.001 versus control*; P = 0.014 versus low dose group#) |
0.60 ± 0.52∗$
(P = 0.0001 versus control*; P = 0.003 versus low dose$) |
|
| ||||
| 8 weeks | Control 8 w | C16 0.5 mg 8 w | C16 1 mg 8 w | C16 2 mg 8 w |
|
| ||||
| Spinal cord | 3.40 ± 0.62 | 2.8 ± 0.84* (P = 0.0052 versus control*) |
1.8 ± 0.4∗#
(P = 0.0021 versus control*; P = 0.005 versus low dose group#) |
1.2 ± 0.45∗$
(P = 0.0014 versus control*; P = 0.0017 versus low dose$) |
| Brain cortex | 2.60 ± 0.67 | 1.4 ± 0.55* (P = 0.0018 versus control*) |
1.2 ± 0.40∗#
(P = 0.001 versus control*; P = 0.04 versus low dose group#) |
1.0 ± 0.71∗$
(P = 0.0009 versus control*; P = 0.01 versus low dose$) |
Data is presented as Mean ± SD. *P < 0.05 was considered statistically significant compared with the control, # P < 0.05 compared with low dose (0.5 mg) C16 treatment group, and $ P < 0.05 compared with low dose (0.05 mg) C16 treatment group.